NSEDisclosure under SEBI Takeover Regulations22 Jun 2026 · 22 Jun 2026, 07:13 pm
Disclosure under SEBI Takeover Regulations
Medicamen Biotech Limited · MEDICAMEQ
✦ AI Summary
Medicamen Biotech Limited has submitted its annual disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing, made by the promoter Shivalik Rasayan Limited, covers the year ended March 31, 2026. It is a routine compliance submission to the exchanges.
Analysis Scores
Earnings Impact5/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Medicamen Biotech Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Attachments (1)
📄pdf
Download →
team_sandeshc_13052026112844_50.pdf
View document text
Date: 07.04.2026
BSE Limited National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G,
Dalal Street Bandra Kurla Complex, Bandra (E)
Mumbai- 400001 Mumbai – 400 051
Code: 531146 Symbol: MEDICAMEQ
Disclosure under Regulation 31(4) of SEBI (SAST) Regulation, 2011
Please find enclosed the yearly disclosure under Regulation 31(4) of SEBI (Substantial
Acquisition of Shares and Takeovers) Regulations, 2011 from the Promoter of the
Company (Shivalik Rasayan Limited) for the year ended on March 31, 2026 for your kind
perusal and record.
For Medicamen Biotech Limited
Parul Choudhary
Company Secretary & Compliance Officer
ACS:44157